Literature DB >> 10531081

Preventing the cardiotoxicity of anthracyclines by dexrazoxane.

K Hellmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10531081      PMCID： PMC1116884          DOI： 10.1136/bmj.319.7217.1085

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.

Authors:  J L Speyer; M D Green; A Zeleniuch-Jacquotte; J C Wernz; M Rey; J Sanger; E Kramer; V Ferrans; H Hochster; M Meyers
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

2.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

Authors:  S M Swain; F S Whaley; M C Gerber; S Weisberg; M York; D Spicer; S E Jones; S Wadler; A Desai; C Vogel; J Speyer; A Mittelman; S Reddy; K Pendergrass; E Velez-Garcia; M S Ewer; J R Bianchine; R A Gams
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

Review 3.  Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.

Authors:  B B Hasinoff; K Hellmann; E H Herman; V J Ferrans
Journal:  Curr Med Chem       Date:  1998-02       Impact factor: 4.530

4.  Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.

Authors:  S M Swain; F S Whaley; M C Gerber; M S Ewer; J R Bianchine; R A Gams
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

5.  Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart.

Authors:  E H Herman; R M Mhatre; I P Lee; V S Waravdekar
Journal:  Proc Soc Exp Biol Med       Date:  1972-05

Review 6.  Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.

Authors:  K A Phillips; I F Tannock
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

Review 7.  Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529).

Authors:  M D Green; P Alderton; J Gross; F M Muggia; J L Speyer
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

8.  Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.

Authors:  F A Bu'Lock; H M Gabriel; A Oakhill; M G Mott; R P Martin
Journal:  Br Heart J       Date:  1993-08

Review 9.  Overview and historical development of dexrazoxane.

Authors:  K Hellmann
Journal:  Semin Oncol       Date:  1998-08       Impact factor: 4.929

10.  Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.

Authors:  L H Wexler; M P Andrich; D Venzon; S L Berg; L Weaver-McClure; C C Chen; V Dilsizian; N Avila; P Jarosinski; F M Balis; D G Poplack; M E Horowitz
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544
View more
  1 in total

Review 1.  Transition metals and mitochondrial metabolism in the heart.

Authors:  Amy K Rines; Hossein Ardehali
Journal:  J Mol Cell Cardiol       Date:  2012-06-02       Impact factor: 5.000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.